The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA.
 
Christian Gratzke
Leadership - European Urology Focus; Urological Research Society
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; GlaxoSmithKline; Ipsen; Janssen; Lilly; Merck Sharp & Dohme; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen
 
Donald Vile
Employment - Blue Ridge Cancer Care
 
Zheng Hong Chen
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Chris Garratt
Employment - Orion
Stock and Other Ownership Interests - Orion
 
Christian Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Jelena Todoric
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Pfizer